{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:52:08Z","timestamp":1792155128964,"version":"4.4.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32573324"],"award-info":[{"award-number":["32573324"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32272965"],"award-info":[{"award-number":["32272965"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32472982"],"award-info":[{"award-number":["32472982"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejphar.2026.179395","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:00:43Z","timestamp":1791039643000},"page":"179395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Taurocholic acid attenuates hepatic inflammation in MASH and modulates the PPAR\u03b3\/NF-\u03baB axis"],"prefix":"10.1016","volume":"1036","author":[{"given":"Yue","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishuang","family":"San","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyi","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179395_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.179395_bib2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2026.179395_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s43066-024-00378-9","article-title":"Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease","volume":"14","author":"Basuni","year":"2024","journal-title":"Egypt. Liver J"},{"key":"10.1016\/j.ejphar.2026.179395_bib4","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1700183","article-title":"The bile acid receptor GPBAR1 regulates the M1\/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis","volume":"199","author":"Biagioli","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.179395_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.livres.2021.08.003","article-title":"Bile acid activated receptors: integrating immune and metabolic regulation in non-alcoholic fatty liver disease","volume":"5","author":"Biagioli","year":"2021","journal-title":"Liver Res"},{"key":"10.1016\/j.ejphar.2026.179395_bib6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metab"},{"key":"10.1016\/j.ejphar.2026.179395_bib7","doi-asserted-by":"crossref","first-page":"18528","DOI":"10.1074\/jbc.M109.099333","article-title":"Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione","volume":"285","author":"Caballero","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.179395_bib8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2026.179395_bib9","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis","volume":"50","author":"Chiang","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2026.179395_bib10","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ejphar.2026.179395_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile acid metabolism in liver pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr."},{"key":"10.1016\/j.ejphar.2026.179395_bib12","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejphar.2026.179395_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164191","article-title":"Evaluation of methionine content in a high-fat and choline-deficient diet on body weight gain and the development of non-alcoholic steatohepatitis in mice","volume":"11","author":"Chiba","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.179395_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jceh.2021.08.017","article-title":"A current understanding of bile acids in chronic liver disease","volume":"12","author":"Farooqui","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.ejphar.2026.179395_bib15","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejphar.2026.179395_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.105.085597","article-title":"Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis","volume":"315","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2026.179395_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2026.179395_bib18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.179395_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13258-023-01455-w","article-title":"ACT001 alleviates inflammation and pyroptosis through the PPAR-\u03b3\/NF-\u03baB signaling pathway in LPS-induced alveolar macrophages","volume":"46","author":"Fu","year":"2024","journal-title":"Genes Genom"},{"key":"10.1016\/j.ejphar.2026.179395_bib20","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","article-title":"A researcher's guide to preclinical mouse NASH models","volume":"4","author":"Gallage","year":"2022","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejphar.2026.179395_bib21","article-title":"A methionine-choline-deficient diet induces nonalcoholic steatohepatitis and alters the lipidome, metabolome, and gut microbiome profile in the C57BL\/6J mouse","volume":"1869","author":"Gautam","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejphar.2026.179395_bib22","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3390\/molecules28052005","article-title":"Taurocholic acid and glycocholic acid inhibit inflammation and activate farnesoid X receptor expression in LPS-stimulated zebrafish and macrophages","volume":"28","author":"Ge","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.179395_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications\u2013a review","volume":"13","author":"Grygiel-G\u00f3rniak","year":"2014","journal-title":"Nutr. J."},{"key":"10.1016\/j.ejphar.2026.179395_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000491","article-title":"Liver macrophages revisited: the expanding universe of versatile responses in a spatiotemporal context","volume":"8","author":"Guillot","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ejphar.2026.179395_bib25","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/cells10061355","article-title":"Epigenetic regulation of peroxisome proliferator-activated receptor gamma mediates high-fat diet-induced non-alcoholic fatty liver disease","volume":"10","author":"Hajri","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.179395_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179395_bib27","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2026.179395_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/liv.15098","article-title":"Changes in bile acid subtypes and long-term successful weight-loss in response to weight-loss diets: the POUNDS lost trial","volume":"42","author":"Heianza","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2026.179395_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bbrc.2005.08.070","article-title":"Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice","volume":"336","author":"Inoue","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2026.179395_bib30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41401-022-00880-z","article-title":"Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease","volume":"43","author":"Jiao","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2026.179395_bib31","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/biom13081264","article-title":"Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease","volume":"13","author":"Kamata","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2026.179395_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2026.179395_bib33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2026.179395_bib34","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/biom13091356","article-title":"Alterations in circulating bile acids in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"13","author":"Lai","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2026.179395_bib35","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-kappaB pathway in inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2026.179395_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejphar.2026.179395_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2026.116525","article-title":"Taurine attenuates diabetic nephropathy by suppressing the HMGB1\/TLR4\/MyD88\/NF-\u03baB axis in mice","volume":"177","author":"Lin","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.179395_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107961","article-title":"Taurine attenuates LPS-induced pro-inflammatory cytokine production in IPEC-J2 cells by inhibiting the TLR4-MyD88\/TRIF signaling pathway","volume":"208","author":"Lin","year":"2025","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.ejphar.2026.179395_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.149366","article-title":"Peroxisome proliferator-activated receptor gamma: a promising therapeutic target for the treatment of chronic pain","volume":"1850","author":"Liu","year":"2025","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2026.179395_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/biology13040243","article-title":"Intestinal barrier dysfunction and gut microbiota in non-alcoholic fatty liver disease: assessment, mechanisms, and therapeutic considerations","volume":"13","author":"Long","year":"2024","journal-title":"Biology"},{"key":"10.1016\/j.ejphar.2026.179395_bib41","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.179395_bib42","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179395_bib43","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1038\/s41467-024-48471-2","article-title":"Liver ACOX1 regulates levels of circulating lipids that promote metabolic health through adipose remodeling","volume":"15","author":"Lu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.179395_bib44","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.179395_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/antiox11010091","article-title":"Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease","volume":"11","author":"Ma","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejphar.2026.179395_bib46","article-title":"Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease","volume":"10","author":"Machado","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.179395_bib47","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00011-023-01765-5","article-title":"Exosomal PPAR\u03b3 derived from macrophages suppresses LPS-induced peritonitis by negative regulation of CD14\/TLR4 axis","volume":"72","author":"Meng","year":"2023","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.ejphar.2026.179395_bib48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPAR\u03b3 deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Mor\u00e1n-Salvador","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2026.179395_bib49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/cimb47020079","article-title":"Advances in understanding lipopolysaccharide-mediated hepatitis: mechanisms and pathological features","volume":"47","author":"Nakadate","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.ejphar.2026.179395_bib50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13105-020-00777-7","article-title":"Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-\u03b21\/Smad signaling pathway","volume":"77","author":"Ni","year":"2021","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2026.179395_bib51","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease \u2013 novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2026.179395_bib52","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","article-title":"TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading","volume":"14","author":"Pols","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2026.179395_bib53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-0041-1731707","article-title":"Role of FXR in bile acid and metabolic homeostasis in NASH: pathogenetic concepts and therapeutic opportunities","volume":"41","author":"Radun","year":"2021","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ejphar.2026.179395_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110207","article-title":"Cross-talk between PPAR\u03b3, NF-\u03baB, and p38 MAPK signaling mediates the ameliorating effects of bergenin against the iron overload-induced hepatotoxicity","volume":"368","author":"Salama","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejphar.2026.179395_bib55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.bjp.0705973","article-title":"GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation","volume":"143","author":"Seargent","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179395_bib56","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.179395_bib57","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcpt.13971","article-title":"The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism","volume":"134","author":"Sun","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2026.179395_bib58","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cgh.2020.06.067","article-title":"A high serum level of taurocholic acid is correlated with the severity and resolution of drug-induced liver injury","volume":"19","author":"Tian","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2026.179395_bib59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","article-title":"Nonalcoholic fatty liver disease: pathology and pathogenesis","volume":"5","author":"Tiniakos","year":"2010","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejphar.2026.179395_bib60","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.bbamcr.2014.05.014","article-title":"Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease","volume":"1843","author":"Turner","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2026.179395_bib61","first-page":"8839","article-title":"PPAR-\u03b3 with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD","volume":"22","author":"Vetuschi","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2026.179395_bib62","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbrc.2015.12.096","article-title":"Suppressing cyclooxygenase-2 prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt\/p53 signal pathway","volume":"469","author":"Wu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2026.179395_bib63","doi-asserted-by":"crossref","first-page":"8624","DOI":"10.1038\/s41467-024-53006-w","article-title":"MDM2 induces pro-inflammatory and glycolytic responses in M1 macrophages by integrating iNOS-nitric oxide and HIF-1\u03b1 pathways in mice","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.179395_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2025.119432","article-title":"Protective effects of taurochenodeoxycholic acid on aflatoxin B1-induced hepatic pyroptosis and gut-liver dysfunction","volume":"307","author":"Xu","year":"2025","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"10.1016\/j.ejphar.2026.179395_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1199519","article-title":"Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions","volume":"11","author":"Xu","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2026.179395_bib66","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7150\/ijbs.87305","article-title":"The role of nuclear receptors in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"20","author":"Yang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejphar.2026.179395_bib67","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2026.179395_bib68","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.ejphar.2026.179395_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1254317","article-title":"A glimpse of the connection between PPAR\u03b3 and macrophage","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179395_bib70","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i8.108606","article-title":"Bile acids in metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Zerem","year":"2025","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ejphar.2026.179395_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2026.121183","article-title":"Myricanol modulates PPAR\u03b3\/ACSL1\/SCD1 metabolic signaling pathway to promote mitochondria biogenesis and fatty acid \u03b2-oxidation in high-fat diet-induced obese mice","volume":"360","author":"Zhang","year":"2026","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2026.179395_bib72","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.3390\/cells11233810","article-title":"A high hepatic uptake of conjugated bile acids promotes colorectal cancer-associated liver metastasis","volume":"11","author":"Zheng","year":"2022","journal-title":"Cells"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926008770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926008770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:19:35Z","timestamp":1792153175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926008770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":72,"alternative-id":["S0014299926008770"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179395","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taurocholic acid attenuates hepatic inflammation in MASH and modulates the PPAR\u03b3\/NF-\u03baB axis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179395"}}